منابع مشابه
Azathioprine-induced pure red-cell aplasia.
Long-term administration of azathioprine is widely used to prevent rejection in organ transplantation and in the treatment of autoimmune diseases. Bone marrow toxicity is a well-known side-effect of azathioprine. Macrocytosis, with or without megaloblastic erythropoiesis in the bone marrow, and (mild) leukopenia are frequently seen [1-4]. Less common effects are anaemia, thrombocytopenia and pa...
متن کاملDiphenylhydantoin-induced pure red cell aplasia.
Pure red cell aplasia is an uncommon complication of diphenylhydantoin therapy. It has not been reported in Indian literature. Awareness of the entity helps in establishing the cause of anaemia in these patients and alerts the physicians to the need of comprehensive haematological monitoring in these patients. A case of 58-year-old male who developed pure red cell aplasia following three months...
متن کاملEpoetin-induced autoimmune pure red cell aplasia.
During the first 10 yr of therapy with recombinant human erythropoietin ([EPO]), only three cases of antibody-associated pure red cell aplasia have been described in patients who were treated with EPO, whereas several millions of patients have received this treatment. Thus, the possibility for epoetin to induce the formation of anti-EPO antibodies was considered extremely low. However, since 19...
متن کاملDiphenyihydantoin - Induced Pure Red Cell Aplasia
The pathogenesis of diphenylhydantoin-induced pure red cell aplasia was investigated in the case of a 32-year-old man who developed pure red cell aplasia while he was under treatment with diphenylhydantoin. The patient’s serum lgG purified from serum drawn at the time of diagnosis suppressed normal allogeneic marrow colonyforming (CFU-E) and burst-forming (BFU-E) and autologous blood BFU-E grow...
متن کاملLenalidomide-Induced Pure Red Cell Aplasia
Pure red cell aplasia (PRCA) is a bone marrow failure disorder. Several drugs have been reported as having induced PRCA, but lenalidomide-induced PRCA is rarely reported. Here we present a patient with myelodysplastic syndrome (MDS) who developed PRCA after treatment with lenalidomide. A 47-year-old male presented with a history of weakness with effort intolerance for 5 months. Examination show...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2003
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.10315